WYE-687 (also known as WYE687) is a small molecule inhibitor of the serine/threonine protein kinase S6K1, which plays a key role in regulating cell growth and metabolism. It has shown promise in preclinical studies for its potential to treat various types of cancer.
Chemical name: N-(4-((2-amino-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-5-(trifluoromethyl)pyridin-2-amine Molecular formula: C19H13F4N5 Formula weight: 391.33 g/mol CAS No: 1062161-90-3
Top ten keywords and synonyms from Google search:
Health benefits of this product include its ability to inhibit the activity of S6K1, which plays a critical role in regulating cell growth and metabolism. By blocking S6K1, WYE-687 can potentially slow down or stop tumor growth in various types of cancer.
Potential effects of WYE-687 include inhibition of tumor growth, induction of apoptosis in cancer cells, and modulation of immune response in various types of cancer. Preclinical studies have shown that WYE-687 can enhance the effectiveness of other anticancer agents when used in combination therapy.
The mechanism of action for WYE-687 involves inhibition of S6K1, a protein kinase that plays a critical role in regulating cell growth and metabolism. By blocking S6K1, WYE-687 can potentially slow down or stop tumor growth in various types of cancer.
Safety is an important consideration when using any therapeutic agent. Preclinical studies have shown that WYE-687 has a favorable safety profile, with no evidence of significant toxicity or adverse effects at therapeutic doses. However, as with any drug, careful monitoring and dose adjustment may be needed to minimize the risk of side effects.
Common side effects associated with WYE-687 include fatigue, nausea, diarrhea, and rash. These side effects are generally mild and self-limiting, and most patients tolerate treatment well.
Dosing information for WYE-687 varies depending on the patient's age, weight, and medical history. It is typically administered orally once daily, and the recommended dose range is 1-100 mg/day.
In conclusion, WYE-687 is a promising small molecule inhibitor of S6K1 that has shown potential as a molecular targeted therapy for various types of cancer. Its ability to regulate cell growth and metabolism makes it a potentially powerful tool for treating diseases characterized by uncontrolled cell growth. While it has a favorable safety profile, careful monitoring and dose adjustment may be necessary to minimize the risk of side effects. Further clinical studies are needed to determine the full therapeutic potential of this compound.
